Dr. Joan Fallon, founder and CEO of Curemark, commented, “Autism is a significant unmet medical need and the treatment for the children is paramount. We are grateful to Mark and his investor group who quickly grasped the important issues surrounding autism and our drug candidate, CM-AT.”
Mark Deutsch, President of Deutsch Capital, said, “Having been in private equity for over 30 years, I’ve invested in many excellent companies across a wide range of industries. But never before have I had the opportunity to invest in a company that has the ability to help so many children throughout the world. Dr. Fallon has conducted groundbreaking research and I believe that CM-AT will become the standard of care for children with autism. We are extremely grateful that Curemark has chosen to work with Deutsch Capital and its large group of investors.”
Curemark is a clinical-stage biopharmaceutical focused on developing novel therapies for the treatment of neurological and other disorders. Headquartered in Rye, NY and established in 2004, the company’s pipeline includes its lead drug candidate, CM-AT, for autism, along with a number of therapies for other neurological conditions. CM-AT, which has been granted Fast Track designation by FDA, is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine. To learn more, visit www.curemark.com.
ABOUT Deutsch CAPITAL
Based in White Plains, NY, Deutsch Capital is a private equity firm that invests in lower middle-market companies across a wide range of industries. Typical investments are in privately owned niche manufacturing, business services and building products companies with sales of $10 million to $100 million. Selectively, the firm also invests in early stage businesses. To learn more, visit www.DeutschCapital.com.